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ABSTRACT
Objective: To report MRI outcomes and explore the
relationship between clinical remission and MRI
inflammation in patients with axial spondyloarthritis
(axSpA) from the RAPID-axSpA trial, including
radiographic (r-)axSpA and non-radiographic (nr-)
axSpA.
Methods: RAPID-axSpA (NCT01087762) was double-
blind and placebo-controlled to week 24, dose-blind to
week 48 and open-label to week 204. Patients were
randomised to certolizumab pegol (CZP) or placebo.
Placebo patients entering dose-blind were
rerandomised to CZP. MRIs performed at baseline,
weeks 12, 48 and 96 were scored by 2 reviewers
independently: Spondyloarthritis Research Consortium
of Canada (SPARCC) for sacroiliac (SI) joints; Berlin
modification of the Ankylosing Spondylitis spine MRI
scoring system for disease activity (Berlin) for spine.
Inflammation thresholds: SPARCC≥2; Berlin>2.
Remission thresholds: SPARCC<2 (SI joints); Berlin≤2
(spine); Ankylosing Spondylitis Disease Activity Score
(ASDAS) inactive disease (<1.3, clinical).
Results: Across 163 patients in the MRI set (109
CZP; 54 placebo), week 12 mean changes from
baseline in MRI scores were greater for CZP versus
placebo: SPARCC: −4.8 (SD 8.6) vs −1.6 (7.8;
p<0.001); Berlin: −2.9 (4.2) vs 0.2 (4.8; p<0.001).
Improvements were maintained to week 96. Week 12
MRI remission was achieved by 52.6% of patients with
baseline MRI inflammation in SI joints, 62.0% in the
spine and 37.9% of patients with both. MRI remission
rates were sustained to week 96, with similar trends in
r-axSpA and nr-axSpA. At week 96, 57.5% vs 65.9%
of patients achieving versus not achieving clinical
remission had MRI remission.
Key messages
What is already known about this subject?
▸ A relationship between MRI inflammation in the
sacroiliac (SI) joints and structural progression
from non-radiographic to radiographic axial
spondyloarthritis (axSpA) has been shown.
However, the relationship between improvement
in clinical disease activity and MRI inflammation
is not well established.
▸ While certolizumab pegol (CZP) has demon-
strated efficacy in clinical and patient-reported
outcomes in radiographic and non-radiographic
axSpA, with improvements maintained to
4 years, its effect on MRI inflammation has not
previously been reported.
What does this study add?
▸ In patients with both radiographic and non-
radiographic axSpA, CZP rapidly reduced inflam-
mation in the spine and SI joints, with improve-
ments sustained over 96 weeks. A substantial
proportion of patients achieved MRI remission,
using stipulated definitions.
▸ No strong associations were seen between clin-
ical remission and the absence of MRI inflam-
mation, either in patients with MRI inflammation
at baseline, or in all patients irrespective of
baseline MRI status.
How might this impact on clinical practice?
▸ The lack of a strong association between clinical
remission and the absence of MRI inflammation
suggests that one cannot be used as a surrogate
for the other by the treating physician.
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Conclusions: CZP reduced inflammation in the spine and SI joints
in patients with r-axSpA and nr-axSpA, with improvements
maintained over 96 weeks. Substantial proportions of patients
achieved MRI remission. Concordance between clinical remission
and current definitions of absence of MRI inflammation was limited.
Trial registration number: NCT01087762; Post-results.
INTRODUCTION
Axial spondyloarthritis (axSpA) is a chronic inﬂamma-
tory disease characterised by inﬂammation of the sacro-
iliac (SI) joints and the spine. AxSpA encompasses
patients with structural changes due to sacroiliitis detect-
able by conventional radiographs and fulﬁlling the
modiﬁed New York (mNY) criteria,1 classiﬁed as having
radiographic axSpA (r-axSpA), or ankylosing spondylitis
(AS), and those not meeting the mNY criteria, classiﬁed
as having non-radiographic axSpA (nr-axSpA).
MRI has emerged as an integral diagnostic tool for
axSpA, as it can identify both active inﬂammation and
structural changes, whereas other imaging modalities
(conventional radiography and CT) can only demon-
strate structural changes.2 This has allowed physicians to
diagnose axSpA earlier, and thus offers the possibility to
initiate early treatment for better symptom relief, aiming
for the prevention of structural damage or halting of
structural progression.3
In addition to the use of MRI as a diagnostic and clas-
siﬁcation tool for patients with axSpA, it can also be
used as an outcome measure to assess the level of
inﬂammation in the spine and SI joints, which poten-
tially aids the decision-making process when considering
treatment with an antitumour necrosis factor (TNF).4 5
A relationship between inﬂammation in the SI joints as
assessed by MRI and structural progression from
nr-axSpA to r-axSpA has been shown,6 7 and there is
accumulating evidence showing an association between
MRI inﬂammation in the spine and syndesmophyte for-
mation.8–12 Currently, clinical disease activity is used to
monitor treatment efﬁcacy in clinical practice. It is still
unclear what role improvements in inﬂammation, as
assessed by MRI, should play in axSpA treatment,13 14 as
the relationship between improvement in clinical disease
activity and improvement in MRI inﬂammation is not
well established.
Certolizumab pegol (CZP) is a pegylated Fc-free
anti-TNF with proven efﬁcacy in clinical and patient-
reported outcomes in r-axSpA and nr-axSpA.15–17 Here,
we use MRI data from 96 weeks of the RAPID-axSpA
trial to address three questions:
1. What is the effect of CZP treatment on inﬂammation
in the spine and SI joints in patients with axSpA,
compared with placebo treatment to week 12, and
during open-label treatment to week 96?
2. What proportion of CZP-treated patients with axSpA
achieve MRI remission in the spine and SI joints?
3. Does clinical remission correlate with the absence of
MRI inﬂammation, that is, can clinical remission be
used as a surrogate for ongoing imaging?
METHODS
Patients
Detailed inclusion and exclusion criteria of the
RAPID-axSpA trial have been previously reported.15 In
brief, eligible patients were aged ≥18 years with a diag-
nosis of adult-onset axSpA, fulﬁlling the Assessment of
Spondyloarthritis (ASAS) criteria,18 of ≥3 months’ dur-
ation and previous treatment failure with ≥1 non-
steroidal anti-inﬂammatory drug. All patients (both
r-axSpA and nr-axSpA) must have had active disease
(Bath AS Disease Activity Index (BASDAI)19 ≥4 and
spinal pain ≥4) and objective signs of inﬂammation (C
reactive protein (CRP) levels >Upper Limit of Normal
(ULN) or evidence of sacroiliitis on MRI). Patients who
had prior exposure to >2 previous biological agents (>1
anti-TNF) for the treatment of axSpA were excluded.
Patients with r-axSpA and nr-axSpA were included in the
study; patients were stratiﬁed based on the presence of
radiographic sacroiliitis at baseline.
Study design
The RAPID-axSpA trial was a 204-week phase 3 multi-
centre trial in patients with axSpA that was double-blind
and placebo-controlled to week 24, dose-blind to week
48 and open-label to week 204. Certain investigator sites
participated in the imaging substudy of the main
RAPID-axSpA trial, which involved MRI of the SI joints
and spine, and spinal X-ray assessments. Here, we report
MRI outcomes from the imaging substudy through to
week 96 of the trial.
Patients were randomised 1:1:1 to placebo, or CZP
400 mg at weeks 0, 2 and 4 (loading dose) followed by
either CZP 200 mg every 2 weeks or CZP 400 mg every
4 weeks. Patients originally randomised to CZP in the
double-blind phase continued on their assigned dose in
the dose-blind and open-label phases. Patients originally
randomised to placebo, who were non-responders
according to the ASAS20 response criteria at weeks 14
and 16, or who completed the 24-week double-blind
phase, entered the dose-blind phase and were rerando-
mised 1:1 to CZP 200 mg every 2 weeks or CZP 400 mg
every 4 weeks following the CZP loading dose (see
online supplementary ﬁgure 1A).
Study assessment
The primary end point of RAPID-axSpA was the week 12
ASAS20 response, which was met and is reported
elsewhere.15 Here, we report imaging data over 96 weeks
of the trial. MRIs of the SI joints and spine were
performed at sites participating in the imaging
substudy using short-τ-inversion-recovery (STIR)
sequences at baseline (±2 weeks), weeks 12, 48 and 96
(see online supplementary ﬁgure 1A). The
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Spondyloarthritis Research Consortium of Canada
(SPARCC) scoring method20 was used for lesions found
in the SI joints on MRI. Total SI joint SPARCC is scored
on a 0–72 scale. The Berlin modiﬁcation of the
Ankylosing Spondylitis spine MRI scoring system for
disease activity (Berlin)21–24 was used for lesions found
in the spine on MRI. Total spine score in the Berlin
modiﬁcation is scored from 0–69.
Data are reported as average scores of the readers
(XB, K-GH, PMM) from the week 96 reading campaign,
where all MRIs from the four MRI assessment time
points (baseline, weeks 12, 48 and 96) were scored by
two expert readers independently, without adjudication
(two of the three readers scored each MRI, based on
reader availability). Average scores of the two readers
were also used to determine whether a patient achieved
the speciﬁed thresholds for remission. Readers were
blinded both to the time point and the treatment
group.
A priori MRI parameters included change from base-
line in SPARCC SI joint scores and Berlin scores for the
spine. Post hoc MRI parameters included the achieve-
ment of MRI remission, deﬁned using the validated
cut-off of SPARCC<2 for the SI joints,25 and the unvalid-
ated cut-off of Berlin score ≤2 for the spine. The
Ankylosing Spondylitis Disease Activity Score
(ASDAS)-CRP was calculated as per van der Heijde26 at
week 96, and clinical remission was deﬁned as ASDAS
inactive disease (ASDAS ID: ASDAS<1.3).27
Statistical analysis
Demographic and baseline characteristics are presented
for the imaging substudy: deﬁned as patients with a valid
baseline and ≥1 postbaseline assessment for either of
the MRI parameters or spinal X-ray. Only observed data
are reported for patients in the imaging set, with no
imputation of missing data.
In this publication, we undertake three different ana-
lyses, to examine three different questions. The speciﬁc
methodology of each of these is described below.
MRI outcomes
In a prespeciﬁed analysis, MRI outcomes at week 12
were compared between CZP and placebo using an ana-
lysis of covariance model with treatment, region, mNY
criteria (yes or no) and prior anti-TNF exposure (yes or
no) as factors and baseline MRI score as the covariate.
Week 12 MRI outcomes are reported separately for
patients originally randomised to CZP (doses combined)
or placebo. Week 48 and 96 outcomes are reported for
all patients, regardless of baseline randomisation (ie,
including patients switching from placebo (PBO) to
CZP).
Achievement of MRI remission
Achievement of MRI remission was analysed in those
patients with MRI evidence of inﬂammation at baseline
only. Evidence of inﬂammation, as assessed by MRI, was
based on the validated threshold of SPARCC≥2 for the
SI joints,25 and the unvalidated thresholds of Berlin
score >2 for the spine. Combined data are reported for
all patients, regardless of baseline randomisation.
Association between clinical remission and the absence of
MRI inflammation
In order to explore whether a correlation exists between
clinical remission and the absence of MRI inﬂammation,
patients from the imaging set in clinical remission at
week 96 were identiﬁed, and subsequently the propor-
tions with/without MRI inﬂammation were calculated
(irrespective of whether MRI inﬂammation was present
at baseline). Combined data are reported, regardless of
baseline randomisation. An additional analysis included
only those patients with evidence of MRI inﬂammation
at baseline, to ask whether patients achieving clinical
remission also achieved a reduction in their MRI
inﬂammation.
RESULTS
Patient disposition and baseline characteristics
Of the 325 patients randomised, 163 were included in
the imaging set. Of these patients, 158 (97%) remained
in the study to week 24, 146 (90%) to week 48 and 132
(81%) to week 96 (see online supplementary ﬁgure
1B).16
Patient demographics and characteristics in the
imaging set (table 1) were comparable to those of the
overall study population at baseline.15 In the imaging
set, there were more men in the r-axSpA group, and
patients with r-axSpA had higher CRP and Bath
Ankylosing Spondylitis Metrology Index (BASMI), but
other baseline demographics and characteristics were
similar between the r-axSpA and nr-axSpA subpopula-
tions. With regard to MRI outcomes, there was a higher
proportion of patients with r-axSpA with spinal inﬂam-
mation on MRI when compared with the nr-axSpA sub-
population, though SI joint inﬂammation was slightly
more common in patients with nr-axSpA (table 1).
At baseline, 43 (28.5%) patients had inﬂammation in
the SI joints and spine, 46 (30.5%) patients had inﬂam-
mation in the SI joints only, 28 (18.5%) patients had
inﬂammation in the spine only, and 34 (22.5%) patients
did not have inﬂammation in either the SI joints or the
spine, as demonstrated by MRI (see online
supplementary table S1). Of patients without sacroiliac
joint (SIJ) inﬂammation at baseline, 6/18 patients with
nr-axSpA (33.3%) and 22/44 patients with r-axSpA
(50.0%) had evidence of spinal inﬂammation.
At baseline, more spinal inﬂammation on MRI (ie, a
higher Berlin score) was observed among patients with
evidence of inﬂammation in the SI joints (SPARCC≥2)
compared with those without (see online supplementary
ﬁgure 2A). Similarly, a greater degree of SI joint inﬂam-
mation on MRI (ie, higher SPARCC SI joint scores) was
observed among patients with evidence of inﬂammation
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Table 1 Baseline demographics and patient characteristics for all patients included in the imaging set
r-axSpA nr-axSpA
Overall r-axSpA
(n=95)
Week 0 CZP
(dose combined)
(n=63)
Placebo
(n=32)
Overall
nr-axSpA
(n=68)
Week 0 CZP
(dose combined)
(n=46)
Placebo
(n=22)
Except where indicated otherwise, values are n (%) at baseline
Age, years, mean (SD) 40.6 (11.6) 40.5 (10.3) 40.8 (13.8) 36.6 (12.9) 36.7 (12.8) 36.2 (13.5)
Gender, male 69 (72.6) 44 (69.8) 25 (78.1) 36 (52.9) 24 (52.2) 12 (54.5)
BMI, mean (SD) 27.2 (5.3) 27.3 (5.5) 26.9 (5.0) 26.4 (5.8) 26.9 (5.8) 25.5 (5.9)
Symptom duration, years, median (minimum, maximum) 9.5 (0.3, 50.9) 8.9 (0.3, 44.8) 9.8 (0.5, 50.9) 5.2 (0.3, 39.6) 5.4 (0.3, 31.4) 5.0 (0.5, 39.6)
Symptom duration, <5 years 33 (34.7) 23 (36.5) 10 (31.3) 34 (50.0) 23 (50.0) 11 (50.0)
Smoking status
Current 21 (22.1) 15 (23.8) 6 (18.8) 20 (29.4) 13 (28.3) 7 (31.8)
Former 18 (18.9) 8 (12.7) 10 (31.3) 13 (19.1) 9 (19.6) 4 (18.2)
Never 56 (58.9) 40 (63.5) 16 (50.0) 35 (51.5) 24 (52.2) 11 (50.0)
Positive for HLA-B27 78 (82.1) 51 (81.0) 27 (84.4) 53 (77.9) 34 (73.9) 19 (86.4)
CRP mg/L, median 14.2 14.0 16.0 10.5 10.5 10.5
SPARCC SI joint score, mean (SD) 7.2 (11.9) 7.2 (11.9) 12.6 (17.1) 7.2 (9.8) 7.2 (9.8) 11.8 (13.5)
SI joint inflammation on MRI (SPARCC≥2) 49 (52.7) 33 (54.1) 16 (50.0) 41 (68.3) 26 (65.0) 15 (75.0)
Berlin, mean (SD) 5.3 (5.9) 5.3 (5.9) 5.5 (7.0) 2.8 (4.2) 2.8 (4.2) 3.2 (7.7)
Spinal inflammation on MRI (Berlin >2) 54 (58.1) 36 (59.0) 18 (56.3) 19 (31.7) 14 (35.0) 5 (25.0)
SI joint and spinal inflammation on MRI (SPARCC≥2 and
Berlin >2)
32 (34.4) 23 (37.7) 9 (28.1) 11 (19.0) 8 (21.1) 3 (15.0)
BASDAI, mean (SD) 6.6 (1.5) 6.5 (1.5) 6.8 (1.7) 6.5 (1.5) 6.5 (1.5) 6.4 (1.4)
BASFI, mean (SD) 6.0 (2.1) 5.9 (2.1) 6.3 (1.9) 4.8 (2.2) 4.8 (2.3) 4.7 (2.0)
BASMI, mean (SD) 4.4 (1.5) 4.2 (1.5) 4.8 (1.5) 2.9 (1.4) 3.0 (1.4) 2.8 (1.3)
ASDAS, mean (SD) 4.0 (0.9) 3.9 (0.8) 4.2 (1.0) 3.7 (0.9) 3.7 (0.8) 3.8 (1.0)
Peripheral arthritis* 36 (37.9) 20 (31.7) 16 (50.0) 29 (42.6) 16 (34.8) 13 (59.1)
Enthesitis† 72 (75.8) 46 (73.0) 26 (81.3) 50 (73.5) 33 (71.7) 17 (77.3)
Extraspinal features of axSpA (either patient history or current diagnosis)
Defined by the ASAS classification criteria screening assessment
Heel enthesitis 38 (40.0) 24 (38.1) 14 (43.8) 25 (36.8) 14 (30.4) 11 (50.0)
Uveitis 22 (23.2) 12 (19.0) 10 (31.3) 14 (20.6) 9 (19.6) 5 (22.7)
Psoriasis 3 (3.2) 2 (3.2) 1 (3.1) 5 (7.4) 4 (8.7) 1 (4.5)
Inflammatory bowel disease 6 (6.3) 3 (4.8) 3 (9.4) 1 (1.5) 0 1 (4.5)
*Defined as ≥1 swollen joint in a 44-joint assessment.
†Defined as a Maastricht Ankylosing Spondylitis Entheses Score (MASES) score >0.
ASDAS, Ankylosing Spondylitis Disease Activity Score; BASDAI, Bath Ankylosing Spondylitis Disease Activity Index; BASFI, Bath Ankylosing Spondylitis Functional Index; BASMI, Bath
Ankylosing Spondylitis Metrology Index; BMI, body mass index; CRP, C reactive protein; CZP, certolizumab pegol; HLA, human leucocyte antigen; nr-axSpA, non-radiographic axial
spondyloarthritis; r-axSpA, radiographic axial spondyloarthritis; SI, sacroiliac; SPARCC, Spondyloarthritis Research Consortium of Canada.
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in the spine compared with those without (see online
supplementary ﬁgure 2B).
MRI outcomes
At week 12, the observed mean change from baseline
(SD) in the SPARCC SI joint score was signiﬁcantly
greater for CZP-treated patients than patients given
placebo: −4.8 (8.6) for patients treated with CZP (dose
combined) compared with −1.6 (7.8) for placebo
(p<0.001; table 2). Corresponding improvements were
seen in the spine for CZP-treated patients, with observed
mean change from baseline scores (SD) in the Berlin
score at week 12 of −2.9 (4.2) in the CZP-treated group
(dose combined) compared with 0.2 (4.8) in the
placebo group (p<0.001; table 2). Similar improvements
in MRI scores were observed with both CZP dosing regi-
mens at week 12 and were also similar in the r-axSpA
and nr-axSpA subpopulations (table 2).
Improvements to week 12 with both MRI outcome
measures were maintained through the dose-blind (to
week 48) and the open-label (to week 96) trial periods
(table 3), with greater improvements seen in patients
with higher levels of inﬂammation at baseline (ﬁgure 1).
Achievement of MRI remission
Placebo-controlled period (week 12 data)
At week 12, among patients with MRI inﬂammation at
baseline, higher proportions of CZP-randomised versus
placebo-randomised patients achieved MRI remission: SI
joint remission was achieved by 30 of 57 (52.6%)
CZP-randomised patients versus 0 of 26 placebo-rando-
mised patients (ﬁgure 2A), and spinal remission was
achieved by 31 of 50 (62.0%) CZP-randomised and 3 of
23 (13.0%) placebo-randomised patients (ﬁgure 2B). Of
patients with both SI joint and spinal inﬂammation at
baseline, 11/29 (37.9%) CZP patients and 0/11 (0.0%)
placebo patients achieved MRI remission of both sites
(ﬁgure 2C). SI joint remission rates were numerically
higher in patients with r-axSpA (61.3%), compared with
patients with nr-axSpA (42.3%); spinal remission rates
were similar between groups (r-axSpA: 61.1%; nr-axSpA:
64.3%).
Notably, among patients without evidence of SI joint
inﬂammation on MRI at baseline, 1 of 40 CZP-treated
patients (2.5%) developed inﬂammation at week 12,
compared with 2 of 19 (10.5%) placebo-treated patients
(all had r-axSpA). Similarly, among patients without MRI
evidence of spinal inﬂammation at baseline, 1 of 49
CZP-treated patients with r-axSpA (2.0%) developed
inﬂammation at week 12 compared with 3 of 26 (11.5%)
placebo-treated patients (1 r-axSpA and 2 nr-axSpA).
Dose-blind and early open-label periods (data to week 96)
MRI remission rates at week 12 were sustained to week
96 for all patients treated with CZP (ie, including
patients rerandomised from placebo to CZP). Similar
trends were observed for patients with r-axSpA and
nr-axSpA, although, as at week 12, patients with r-axSpA
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Table 3 Improvement from baseline scores in SPARCC (SI joints) and Berlin (spine) at weeks 48 and 96 of the
RAPID-axSpA trial for all patients in the imaging set (observed data)
All CZP (dose combined)
N
Mean score at
baseline (SD)* Mean score (SD)
Mean change from
baseline (SD)
SPARCC (SI joints)
Week 48
axSpA 113 9.0 (13.3) 2.7 (5.7) −6.3 (12.7)
r-axSpA 61 9.6 (14.9) 2.0 (4.5) −7.6 (13.0)
nr-axSpA 52 8.3 (11.3) 3.5 (6.9) −4.8 (12.2)
Week 96
axSpA 125 9.2 (13.1) 2.1 (6.2) −7.2 (12.6)
r-axSpA 77 9.5 (14.1) 1.4 (5.6) −8.1 (12.7)
nr-axSpA 48 8.8 (11.4) 3.2 (7.0) −5.6 (12.4)
Berlin (spine)
Week 48
axSpA 114 3.8 (5.7) 1.4 (2.6) −2.4 (4.4)
r-axSpA 62 4.6 (5.6) 1.7 (3.2) −2.9 (4.0)
nr-axSpA 52 2.9 (5.7) 1.0 (1.5) −1.9 (4.7)
Week 96
axSpA 126 4.7 (6.2) 1.4 (2.5) −3.3 (5.1)
r-axSpA 78 5.6 (6.3) 1.6 (2.9) −4.0 (5.1)
nr-axSpA 48 3.3 (5.9) 1.0 (1.7) −2.3 (5.0)
Patients randomised to placebo at baseline received CZP from week 16 (if escaping early), or week 24 (if completing double-blind phase) and
are included in weeks 48 and 96 results.
*Matched baseline readings; in the week 96 reading campaign, MRIs from each previous visit were re-read.
axSpA, axial spondyloarthritis; CZP, certolizumab pegol; nr-axSpA, non-radiographic axial spondyloarthritis; r-axSpA, radiographic axial
spondyloarthritis; SI, sacroiliac; SPARCC, Spondyloarthritis Research Consortium of Canada.
Figure 1 Baseline scores and corresponding changes to week 96 of the RAPID-axSpA trial for all CZP-treated patients
included in the imaging substudy for: (A) SPARCC SI joint scores, (B) Berlin score for the spine. Patients randomised to placebo
at baseline received CZP from week 16 (if escaping early), or week 24 (if completing a double-blind phase) and are included in
these results. axSpA, axial spondyloarthritis; CZP, certolizumab pegol; SI, sacroiliac; SPARCC, Spondyloarthritis Research
Consortium of Canada.
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tended to have higher rates of MRI remission of the SI
joints than patients with nr-axSpA (ﬁgure 2A–C). The
majority of patients who achieved the speciﬁed thresh-
olds for remission at week 12 sustained these results to
week 96 (60.0% of those with SI joint remission, 88.2%
of those with Berlin spine remission). Among those who
did not achieve remission at week 12, only 26.4%
(SPARCC SI joint) and 33.3% (Berlin spine) subse-
quently achieved remission at weeks 48 and 96 (data not
shown). A summary of patients achieving SI joint, Berlin
spine and both SI joint and Berlin spine remission is
shown in online supplementary ﬁgure S3.
In patients with MRI evidence of inﬂammation in the
SI joints and spine at baseline, MRI remission of SI
joints and spinal inﬂammation occurred with similar fre-
quency to week 96 (24 (63.2%) and 26 (68.4%) of 38
patients, respectively).
Associations between clinical and MRI remission
Further investigations assessed whether achievement of
clinical remission was associated with the absence of
MRI inﬂammation. All patients were included, irrespect-
ive of whether MRI inﬂammation was present at
baseline.
A third of all patients achieved clinical remission at
week 96 (33.3%; 41/123). Of these patients, 63.4% (26/
41) also did not have MRI inﬂammation (SPARCC<2) of
the SI joints (ﬁgure 3A). However, of the 82 patients
who did not achieve clinical remission, 65 (79.3%) also
did not have MRI inﬂammation of the SI joints,
Figure 2 MRI remission in the imaging set of patients from
the RAPID-axSpA trial. Remission rates to week 96 in patients
with (A) SI joint inflammation, (B) spinal inflammation and (C)
both SI joint and spinal. Observed case data shown at week
12 for patients randomised to CZP at baseline and for all
patients regardless of baseline randomisation thereafter.
axSpA, axial spondyloarthritis; CZP, certolizumab pegol;
nr-axSpA, non-radiographic axial spondyloarthritis; r-axSpA,
radiographic axial spondyloarthritis; SI, sacroiliac.
Figure 3 Correlations between clinical remission and MRI
inflammation of the (A) SI joints, (B) spine and (C) both SI
joints and spine, at week 96 of the RAPID-axSpA trial for all
patients with axSpA in the imaging set. ASDAS, Ankylosing
Spondylitis Disease Activity Score; axSpA, axial
spondyloarthritis; SI, sacroiliac; SPARCC, Spondyloarthritis
Research Consortium of Canada.
Braun J, et al. RMD Open 2017;3:e000430. doi:10.1136/rmdopen-2017-000430 7
Imaging
group.bmj.com on August 31, 2017 - Published by http://rmdopen.bmj.com/Downloaded from 
suggesting that clinical remission and MRI SI joint
inﬂammation are not closely associated.
High proportions of patients both achieving and not
achieving clinical remission at week 96 had no spinal
inﬂammation on MRI (92.5% of patients achieving, and
78.6% of patients not achieving clinical remission;
ﬁgure 3B), again indicating a lack of correlation
between clinical remission and MRI inﬂammation.
When considering MRI inﬂammation of the SI joints
and the spine, this was achieved with similar frequency
regardless of the week 96 clinical remission state
(ﬁgure 3C). Achievement of MRI and clinical remission
did not differ greatly between the r-axSpA and nr-axSpA
subpopulations (see online supplementary ﬁgure S4).
In addition to determining whether patients achiev-
ing/not achieving clinical remission met the speciﬁed
thresholds for MRI inﬂammation, we examined
summary statistics of MRI parameters in patients with
clinical remission or other categories of disease activity
(ASDAS moderate disease activity, high disease activity
and very high disease activity). Again, no strong correla-
tions were seen between MRI parameters and disease
activity (see online supplementary table S2).
In order to examine a possible association between
clinical remission and MRI remission (ie, a reduction in
MRI inﬂammation), we assessed only those patients with
evidence of MRI inﬂammation at baseline. Similar to the
analyses above, no strong associations were seen between
clinical remission and MRI remission: spinal remission
was seen in only slightly higher proportions of patients
achieving versus not achieving clinical remission (82.4%
of patients achieving vs 68.8% of patients not achieving
clinical remission). Trends were similar in patients with
r-axSpA and nr-axSpA (see online supplementary ﬁgure
S5). When looking at SI joint remission, the opposite
(weak) trend was observed; SIJ remission was achieved by
44.4% of patients who did achieve clinical remission,
versus 68.9% of patients who did not.
DISCUSSION
The results reported here from the RAPID-axSpA trial
demonstrate that CZP treatment of patients with axSpA
signiﬁcantly reduced MRI inﬂammation in the SI joints
and spine over 12 weeks; these improvements were seen
across the broad axSpA population, including patients
with r-axSpA and nr-axSpA. Improvements in MRI scores
were maintained through to week 96 for patients treated
with CZP, including patients originally randomised to
placebo. Furthermore, when stipulated thresholds for
remission of inﬂammation, as demonstrated by MRI,
were applied to these data, over half of all patients with
baseline inﬂammation in either the SI joints or spine,
and at least a third of patients with inﬂammation in
both, achieved week 12 MRI remission, which was sus-
tained to week 96.
Results from previous studies have demonstrated the
effectiveness of anti-TNFs in improving long-term MRI
outcomes in patients with r-axSpA,28–31 and short-term
MRI outcomes in patients with nr-axSpA.32 33
Additionally, results from the ESTHER trial have demon-
strated similar responses in MRI outcomes in patients
with r-axSpA and nr-axSpA over 3 years of treatment
with etanercept, though the patient numbers in this
study were small (31 patients with r-axSpA and 30 with
nr-axSpA).34 This is the ﬁrst report demonstrating long-
term (2 years) maintenance of improvements in MRI
outcomes in a large patient population (N=163) contain-
ing both patients with r-axSpA and nr-axSpA treated
with an anti-TNF.
At baseline, there was no difference observed in the
level of inﬂammation in the SI joints between the
r-axSpA and nr-axSpA subpopulations (ie, mean
SPARCC score), but a slightly higher proportion of
patients with nr-axSpA had deﬁnite evidence of inﬂam-
mation (ie, SPARCC score ≥2) than patients with
r-axSpA. In contrast, patients with r-axSpA had a greater
level of inﬂammation in the spine at baseline than
patients with nr-axSpA, with approximately one-half of
patients with r-axSpA compared with one-third of
patients with nr-axSpA having deﬁnite evidence of
inﬂammation in the spine at baseline. We also noted
that a substantial proportion (33.3%) of patients with
nr-axSpA without SI joint inﬂammation had evidence of
spinal inﬂammation on MRI. This is in agreement with
data from the ABILITY-1 trial,35 which concluded that
spinal inﬂammation may be present in up to half of the
patients with nr-axSpA without SIJ inﬂammation.
In the overall axSpA population, baseline data sug-
gested a relationship between inﬂammation in the SI
joints and the spine. Presence of SI joint inﬂammation
at baseline was associated with higher spinal MRI scores
than in those with absence of inﬂammation at baseline.
The same was true for spinal inﬂammation and SI joint
MRI scores, with greater SI joint MRI scores observed in
patients with spinal inﬂammation at baseline than those
without.
Since it is impractical to conduct frequent MRIs in
clinical practice, the question of whether patients in clin-
ical remission have concurrent absence of axial inﬂam-
mation is an important one to help determine whether
ongoing imaging is necessary. The ﬁndings from the
present study suggest a lack of correlation between the
achievement of clinical remission and lack of MRI evi-
dence of inﬂammation at week 96 in patients with
axSpA treated with CZP. Similar conclusions have been
drawn in a previous study in patients with r-axSpA,
which found that both ASAS responders and non-
responders showed signiﬁcant reductions in MRI inﬂam-
mation over 52 weeks of treatment.31 These ﬁndings
suggest that clinical remission cannot be taken as a sur-
rogate of MRI remission by the treating physician.
Ongoing inﬂammation in the spine has been linked
to structural progression,13 36 and while incorporating
imaging into future treatment targets has been pro-
posed, paucity of evidence precludes such a
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recommendation, where monitoring of MRI inﬂamma-
tion also has limited application in clinical practice.37
Further research into the use of MRI outcomes as
targets for treatment is required to fully understand the
extent to which this inﬂammation relates to structural
progression and long-term outcomes.
The analyses reported here are not without limitation.
The exploratory, post hoc analyses evaluating the associ-
ation between clinical and MRI remission at week 96
should be interpreted with care, as patient withdrawal
over the course of the study could bias the remaining
population and impact on these results. Additionally, it
should be noted that the deﬁnition of spinal remission
used here (Berlin ≤2) has not been validated, and
recent data suggest that at least ﬁve inﬂammatory (or
fatty) lesions detectable by MRI may be required to dif-
ferentiate patients with axSpA from those with no SpA,
at a level of 95% speciﬁcity.38 However, here we use this
threshold not to differentiate between patients with and
without axSpA, but within a population of patients
already diagnosed with axSpA, to assess their MRI
inﬂammation.
In summary, CZP treatment was shown to rapidly
reduce inﬂammation in the spine and SI joints in
patients with axSpA, including both patients with
r-axSpA and nr-axSpA, with these improvements main-
tained over 96 weeks. A substantial proportion of
patients also achieved MRI remission of inﬂammation.
Furthermore, it was demonstrated that clinical remission
was not associated with the absence of MRI inﬂamma-
tion, suggesting that one cannot be used as a surrogate
for the other.
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